August 20, 2018 03:15 PM EDT
R&D

Novo's new tri­al re­sults stoke block­buster hopes, with oral semaglu­tide scor­ing again in Phase II­Ia

Brittany Meiling

No­vo Nordisk is build­ing a block­buster case for its di­a­betes drug semaglu­tide, trot­ting out Phase II­Ia tri­al re­sults Mon­day that show its new pill ver­sion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times